Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc. - Class A Common Shares (NQ: CRDL )

1.259 +0.009 (+0.73%)
Streaming Delayed Price Updated: 11:58 AM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 135,745
Open 1.280
Bid (Size) 1.250 (17)
Ask (Size) 1.260 (14)
Prev. Close 1.250
Today's Range 1.240 - 1.280
52wk Range 0.8110 - 3.120
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”
Via AB Newswire
3 Penny Stocks Ready to Break Out in 2025
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products. 
Via MarketBeat

Performance

YTD
+43.08%
+43.08%
1 Month
-18.24%
-18.24%
3 Month
-45.26%
-45.26%
6 Month
-37.04%
-37.04%
1 Year
+51.01%
+51.01%

More News

Read More
Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!
Via AB Newswire
“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
Via AB Newswire
Topics Economy
Exposures Supply Chain
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today
Via Benzinga
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
Via AB Newswire
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
Via Benzinga
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Via AB Newswire
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Via Newsfile
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
Via AB Newswire
Topics Electric Vehicles
Exposures Electric Vehicles Product Safety
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
Via AB Newswire
Exposures Product Safety
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
Via AB Newswire
Topics Government
Exposures Political
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
Via AB Newswire
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”
Via AB Newswire
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Via TheNewswire.com
Exposures Product Safety
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Via News Direct
Exposures Product Safety
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Exposures Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via TheNewswire.com
Topics ETFs
Exposures Product Safety
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
Via AB Newswire
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Via News Direct
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.